Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer’s Disease: A Case-series Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Suvorexant, an orexin receptor antagonist used for insomnia, has been shown to have a preventive effect on delirium in a randomized placebo-controlled trial. However, its effectiveness in the management of nocturnal delirium has not yet been determined. Here we report four cases in which elderly patients with moderate to severe Alzheimer’s disease who developed nocturnal delirium were treated with suvorexant. In case 1, 15 mg suvorexant was initiated to manage nocturnal delirium refractory to antipsychotics, antidepressants, and a Japanese herbal medicine, resulting in immediate sleep improvement. However, treatment discontinuation led to recurrence of symptoms, which were reversed by recommencing suvorexant. In case 2, as antipsychotics used for the treatment of nocturnal delirium were ineffective, 15 mg suvorexant was administered. The patient achieved rapid improvement in sleep. In case 3, the use of atypical antipsychotics for the treatment of nocturnal delirium was contraindicated, as the patient had diabetes. Therefore, 15 mg suvorexant was administered following good outcomes in cases 1 and 2, resulting in immediate sleep improvement. Finally, in case 4, 15 mg suvorexant was used as an initial medication for nocturnal delirium, and the patient showed sleep improvement immediately. Elevated orexin levels in the cerebrospinal fluid are reportedly linked to sleep deterioration in patients with moderate to severe Alzheimer’s disease. The immediate and reproducible action and effectiveness of suvorexant observed in our patients suggest that enhanced cerebral orexin activity might be associated with sleep-wake cycle disturbances due to delirium in elderly patients with Alzheimer’s disease.
Abstract
Suvorexant, an orexin receptor antagonist used for insomnia, has been shown to have a preventive effect on delirium in a randomized placebo-controlled trial. However, its effectiveness in the management of nocturnal delirium has not yet been determined. Here we report four cases in which elderly patients with moderate to severe Alzheimer’s disease who developed nocturnal delirium were treated with suvorexant. In case 1, 15 mg suvorexant was initiated to manage nocturnal delirium refractory to antipsychotics, antidepressants, and a Japanese herbal medicine, resulting in immediate sleep improvement. However, treatment discontinuation led to recurrence of symptoms, which were reversed by recommencing suvorexant. In case 2, as antipsychotics used for the treatment of nocturnal delirium were ineffective, 15 mg suvorexant was administered. The patient achieved rapid improvement in sleep. In case 3, the use of atypical antipsychotics for the treatment of nocturnal delirium was contraindicated, as the patient had diabetes. Therefore, 15 mg suvorexant was administered following good outcomes in cases 1 and 2, resulting in immediate sleep improvement. Finally, in case 4, 15 mg suvorexant was used as an initial medication for nocturnal delirium, and the patient showed sleep improvement immediately. Elevated orexin levels in the cerebrospinal fluid are reportedly linked to sleep deterioration in patients with moderate to severe Alzheimer’s disease. The immediate and reproducible action and effectiveness of suvorexant observed in our patients suggest that enhanced cerebral orexin activity might be associated with sleep-wake cycle disturbances due to delirium in elderly patients with Alzheimer’s disease.
참고문헌 (15)
- Sutton EL, "Profile of suvorexant in the management of insomnia", Drug Des Devel Ther, 9, pp.6035~6042 (2015)
- Hatta K, "Preventive effects of suvorexant on delirium : a randomized placebo-controlled trial", J Clin Psychiatry, 78, pp.e970~ (2017)[DOI]
- Jackson P, "Delirium in critically ill patients", Crit Care Clin, 31, pp.589~603 (2015)
- Fick DM, "Delirium superimposed on dementia is associated with prolonged length of stay and poor outcomes in hospitalized older adults", J Hosp Med, 8, pp.500~505 (2013)
- Inouye SK, "Delirium in older persons", N Engl J Med, 354, pp.1157~1165 (2006)
- Saito S, "Effectiveness of Japanese herbal medicine yokukansan for alleviating psychiatric symptoms after traumatic brain injury", Psychogeriatrics, 10, pp.45~48 (2010)
- Okamoto Y, "Trazodone in the treatment of delirium", J Clin Psychopharmacol, 19, pp.280~282 (1999)
- Friedman JI, "Pharmacological treatments of non-substance-withdrawal delirium : a systematic review of prospective trials", Am J Psychiatry, 171, pp.151~159 (2014)
- Dong Woo Kang, "Role of Sleep Disturbance in the Trajectory of Alzheimer’s Disease", Clinical Psychopharmacology and Neuroscience, 15(2), pp.89~99 (2017), 대한정신약물학회[DOI]
- Fitzgerald JM, "Delirium : a disturbance of circadian integrity", Med Hypotheses, 81, pp.568~576 (2013)
- Maldonado JR, "Neuropathogenesis of delirium : review of current etiologic theories and common pathways", Am J Geriatr Psychiatry, 21, pp.1190~1222 (2013)
- Hatta K, "Preventive effects of ramelteon on delirium : a randomized placebo-controlled trial", JAMA Psychiatry, 71, pp.397~403 (2014)
- Furuya M, "Marked improvement in delirium with ramelteon : five case reports", Psychogeriatrics, 12, pp.259~262 (2012)
- Kimura R, "Treatment of delirium with ramelton : initial experience in three patients", Gen Hosp Psychiatry, 33, pp.407~409 (2011)
- Liguori C, "Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease", JAMA Neurol, 71, pp.1498~1505 (2014)